drugset / Trial / NCT04322123

Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)

NCT04322123

RandomizedParallel-groupOpen-labelTreatment

Summary

Coronavirus (COVID-19) is a somewhat new and recognized infectious disease that is now spreading to several countries in the world, including Brazil. Hydroxychloroquine and azithromycin may be useful for treating those patients. COALITION I study aims to compared standard of care, hydroxychloroquine plus azithromycin and hydroxychloroquine monotherapy for treatment of hospitalized patients with COVID-19. COALITION I will recruit 630 patients with infection by COVID-19 (210 per arm). Ordinal endpoint of status at 15 days will be the primary endpoint.

Timeline

Start
2020-04-01
Primary completion
2020-06-02
Completion
2020-06-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 500 mg
Subject Hydroxychloroquine Small molecule 400 mg Oral

Indications